[EN] 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS [FR] 5-TRIFLUOROMÉTHYL-OXADIAZOLES SUBSTITUÉS EN 3-ARYLE ET HÉTÉROARYLE EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6 (HDAC6)
[EN] 3- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS [FR] 5-TRIFLUOROMÉTHYL-OXADIAZOLES SUBSTITUÉS PAR UN 3-HÉTÉROARYLE À TITRE D'INHIBITEURS D'HISTONE DÉSACÉTYLASE 6 (HDAC6)
[EN] 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS<br/>[FR] 5-TRIFLUOROMÉTHYL-OXADIAZOLES SUBSTITUÉS EN 3-ARYLE ET HÉTÉROARYLE EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6 (HDAC6)
申请人:MERCK SHARP & DOHME
公开号:WO2017222951A1
公开(公告)日:2017-12-28
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
Pyridines Substituted with Five Different Elements
作者:Fredrik von Kieseritzky、Johan Lindström
DOI:10.1055/s-0029-1217084
日期:2010.1
By stepwise and regioselective installation of functional groups, we have synthesized and characterized two pyridines, 3-fluoro-5-iodo-2-(methylthio)-6-(trimethylsilyl)isonicotinonitrile and 3-fluoro-5-iodo-2-methoxy-6-(trimethylsilyl)isonicotinonitrile, substituted with five different elements, not including hydrogen, using known and newly developed methods. Novel methodology for dehalocyanation of iodopyridines and rapid, high-yielding microwave-assisted acidic hydrolysis of 2-fluoropyridines to their corresponding 2-pyridones are disclosed.
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
申请人:Merck Sharp & Dohme Corp.
公开号:US11066396B2
公开(公告)日:2021-07-20
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.
本发明涉及通式(I)的取代的5-三氟甲基噁二唑化合物或其药学上可接受的盐。特别是,本发明涉及一类式 I 的芳基和杂芳基取代的 5-三氟甲基噁二唑化合物,其可作为 HDAC6 抑制剂用于治疗细胞增殖性疾病,包括癌症、神经退行性疾病(如精神分裂症和中风)以及其他疾病。
3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:EP3475275A1
公开(公告)日:2019-05-01
3-ARYL- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONEDEACETYLASE 6 (HDAC6) INHIBITORS
申请人:Merck Sharp & Dohme Corp.
公开号:US20190185462A1
公开(公告)日:2019-06-20
The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.